Vanda Pharmaceuticals, Inc. (VNDA)
7.17
-0.10
(-1.38%)
USD |
NASDAQ |
Apr 20, 09:51
Vanda Pharmaceuticals SG&A Expense (Quarterly) : 62.98M for Dec. 31, 2025
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Eli Lilly & Co. | 3.132B |
| Gilead Sciences, Inc. | 4.418B |
| Gossamer Bio, Inc. | 10.90M |
| BridgeBio Pharma, Inc. | 158.08M |
| Arcellx, Inc. | 31.24M |